SUN-234 Effect of Testosterone Undecanoate on Metabolic Syndrome Parameters in a Cohort of Hypogonadism

Objective: To study the prevalence of metabolic syndrome (MS) and whole-body composition in hypogonadism and studied the effects of replacement of testosterone. Methods: In a single centre prospective case control study, 33 patients with hypogonadism patients (ages 20-39 years) were studied for the effect of testosterone replacement on MS and its components and whole body composition. Results: The prevalence of MS was similar in patients and controls (21% vs. 9.1%, p = 0.3). Prevalence of hypertension was higher in patients than the control (33% vs. 3%, p = 0.00). There was no difference between patients and control in weight, BMI, waist circumference (WC) and whole body composition except for an increase in lean body mass in patients (45908 ± 7969 gm/cm(2) vs. 50712 ±7458 gm/cm(2), p=0.02). After testosterone replacement, there was significant decrease in WC (88.5 ± 13.0 cm vs. 83.9 ± 12.8 cm, p < 0.01), truncal fat, total body fat, fat mass index, fasting C-peptide (2.1 ± 0.78 ng/ml vs. 0.68 ± 0.23 ng/ml, p<0.01), serum pro insulin (1.43 pmol/l (0.32-13.4) vs. 0.5 (0.5-3.2) and a significant increase in lean mass (46906 ± 8876 gm/cm2 vs. 50083 ± 7590 gm/cm2, p <0.001). HOMA-IR (4.6±1.7 vs. 0.5±0.17, p<0.001), HOMA% β (330 ± 103 vs. 66 ± 20, p<0.001) were decreased significantly following testosterone replacement. Conclusion: Testosterone replacement resulted in significant decrease in WC and truncal fat leading to improved insulin sensitivity as evidenced by decreasing serum C-peptide, serum proinsulin levels, decreased beta cell function and decreased insulin resistance.